Aug 23, 2025 — What if HIV treatment moved beyond management and towards a real cure? The Wistar Institute has just announced a groundbreaking $17 million NIH-funded project to launch the iCure Consortium, a collaborative effort aimed at developing personalized HIV cure regimens.
With 38 million people still living with HIV worldwide, the iCure program takes a bold approach: instead of a one-size-fits-all treatment, it tailors six innovative strategies to each person’s unique form of HIV.
How iCure Works:
Wake the latent virus hiding in the body
Map and target each person’s weak spots with custom antibodies
Use engineered CAR-T cells and NK cells to destroy infected cells
Enhance immune clearance and prevent relapse with bispecific binders
Led by Dr. Luis J. Montaner and Nobel Laureate Dr. Drew Weissman, iCure brings together leading institutions like Johns Hopkins, UPenn, MIT, Duke, Harvard’s Ragon Institute, and more.
This video breaks down:
What makes iCure different from current HIV treatments
How the six-part cure strategy works step by step
Why personalized medicine could be the key to ending HIV
The future impact on clinical trials and patients
Ending HIV demands more than management—it demands eradication. iCure may be the step that brings us closer to a durable, drug-free remission.
